戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ndividuals with diabetes among patients with diastolic heart failure.
2 sfunction and serum BNP levels in diagnosing diastolic heart failure.
3 ria set forth by the European Study Group on Diastolic Heart Failure.
4 nderlying etiology to prevent progression to diastolic heart failure.
5 ntricular ejection fraction are said to have diastolic heart failure.
6 is magnified by the increasing prevalence of diastolic heart failure.
7 nfirm rather than establish the diagnosis of diastolic heart failure.
8 nt of new therapeutics for both systolic and diastolic heart failure.
9 ardiac cells, is a major clinical outcome of diastolic heart failure.
10 l dysfunction, increased blood pressure, and diastolic heart failure.
11 Third, among people with chronic systolic or diastolic heart failure, aldosterone is actually produce
12 who met the diagnostic criteria for definite diastolic heart failure; all the patients had signs and
13 atory patients with chronic mild to moderate diastolic heart failure and normal sinus rhythm receivin
14 h among titin alterations in systolic and in diastolic heart failure and ponder the evidence for titi
15  physiology of diastole, the pathogenesis of diastolic heart failure, and the diagnosis of diastolic
16             Further studies of patients with diastolic heart failure are needed to assess its prevale
17 fted up and to the left in the patients with diastolic heart failure as compared with the controls.
18  the xenograft developed rapidly progressing diastolic heart failure, biventricular wall thickening a
19                             The diagnosis of diastolic heart failure can be made without the measurem
20 t failure patients in the United States have diastolic heart failure (clinical heart failure with nor
21                                Patients with diastolic heart failure (DHF) have significant abnormali
22                                              Diastolic heart failure (DHF) is the culmination of vari
23 ce of systolic and diastolic dyssynchrony in diastolic heart failure (DHF) patients and identify the
24 ic heart failure (SHF) and 399 patients with diastolic heart failure (DHF), 12% of whom were classifi
25       These patients, often presumed to have diastolic heart failure (DHF), appear to have lower shor
26 xercise intolerance in elderly patients with diastolic heart failure (DHF).
27 ugh our patients fulfilled the criteria for "diastolic heart failure," diastolic dysfunction was not
28 y hypertension in the absence of systolic or diastolic heart failure (e.g. prostaglandins, endothelin
29                                              Diastolic heart failure easily can be diagnosed by compr
30 amination cannot distinguish these patients (diastolic heart failure) from those with a depressed eje
31                            The patients with diastolic heart failure had abnormal left ventricular re
32           Unfortunately, chronic therapy for diastolic heart failure has not yet been standardized du
33                            The management of diastolic heart failure has two major objectives.
34 ge BNP levels in patients with decompensated diastolic heart failure have been prognostic with respec
35                                  Among them, diastolic heart failure (heart failure due to diastolic
36 nd who underwent cardiac transplantation for diastolic heart failure, her father with left ventricula
37  35+/-9%) or echocardiographically confirmed diastolic heart failure (HF) to assess telephonic DM ove
38                                              Diastolic heart failure (ie, heart failure with preserve
39 d stiffness contribute to the development of diastolic heart failure in other settings.
40 s been studied as a therapeutic strategy for diastolic heart failure, in which slow Ca(2+) reuptake i
41 rized by maladaptive myocardial hypertrophy, diastolic heart failure, increased myofilament Ca(2+) se
42  heart failure induced by pressure overload, diastolic heart failure induced by high-fat diet and nit
43  and functional changes more consistent with diastolic heart failure instead of the commonly taught d
44                                   Therapy of diastolic heart failure is aimed at preventing and reduc
45  failure with preserved ejection fraction or diastolic heart failure is an increasingly prevalent dis
46                             The diagnosis of diastolic heart failure is generally made in patients wh
47 dysfunction, or to distinguish systolic from diastolic heart failure, is not supported by current dat
48 ms functions until postoperative day 47 when diastolic heart failure occurred.
49 goxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Invest
50 ise intolerance that is prominent in elderly diastolic heart failure patients.
51 ove CLinical Status And EXercise Capacity in Diastolic Heart Failure (RELAX) clinical trial (n=216) u
52 ove Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial, physiological var
53                                   Therefore, diastolic heart failure should always be considered when
54 t was significantly higher in the group with diastolic heart failure than in the control group (0.03+
55 e decline (tau) was longer in the group with diastolic heart failure than in the control group (59+/-
56                            In the setting of diastolic heart failure, the cardiac chambers are nondil
57 e involvement of the heart, characterized by diastolic heart failure, the presence of amyloid deposit
58 trates may improve symptoms in patients with diastolic heart failure, there are few data to indicate
59 diabetic myocardium may mediate fibrosis and diastolic heart failure, while preserving matrix homeost
60 ove Clinical Status and Exercise Capacity in Diastolic Heart Failure with Preserved Ejection Fraction
61 iative to treat more than 6000 patients with diastolic heart failure with spironolactone is in its fi